RecruitingNot ApplicableNCT06441617

Confirmatory Trial for Alleviating Fatigue in Multiple Sclerosis


Sponsor

Accelerated Cure Project for Multiple Sclerosis

Enrollment

2,000 participants

Start Date

Dec 5, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

CAFE-MS will assess the effectiveness of two online programs for fatigue in multiple sclerosis (MS). Although they differ, both of these online programs contain information about MS and fatigue intended to help people with MS understand and manage their fatigue. This large-scale, decentralized clinical trial is projected to enroll 2,000 people with MS. The collaboration between iConquerMS and 5 Veterans Affairs (VA) sites in the MS Centers of Excellence is designed to ensure sufficient representation of people with MS from populations traditionally under-represented in MS clinical trials. The study is a 3-arm, randomized controlled clinical trial with study participation lasting 1 year. Two of the trial arms will include one of two online programs for managing fatigue in MS added to the trial participants' usual MS treatment, and the third arm will include usual MS treatment alone. The online program phase of the trial lasts for 6 months after randomization followed by a final study visit at 12 months. Participants in the usual MS treatment alone arm for the first 6 months will have an opportunity to choose one of the online programs for the final 6 months of the trial.


Eligibility

Min Age: 22 Years

Inclusion Criteria10

  • Informed consent by person with MS
  • Living in the US
  • Age ≥ 22
  • Confirmed diagnosis of MS by a physician, who is a neurologist or has access to a neurologist's statement of diagnosis
  • Fatigue Severity Scale score at or above eligibility threshold
  • Fluent in English
  • Willingness to engage in self-administration of an online intervention for 24 weeks and complete follow-up assessments
  • Access to the internet and e-mail with a compatible device (smartphone, computer, or tablet)
  • No MS relapse / no steroid treatment in the 4 weeks prior to answering the screening questionnaire (self-reported)
  • No disease-modifying therapeutic (DMT) started in the 4 weeks prior to answering the screening questionnaire (self-reported)

Exclusion Criteria3

  • Unwilling or unable to consent
  • Refusal to saving, processing and forwarding of pseudonymized data
  • Concurrent participation in another interventional trial

Interventions

DEVICEOnline Program for Fatigue

An MS-specific fatigue management program, delivered as a stand-alone, fully automated intervention via an internet-browser.


Locations(6)

Washington VA Medical Center

Washington D.C., District of Columbia, United States

Baltimore VA Medical Center

Baltimore, Maryland, United States

iConquerMS

Waltham, Massachusetts, United States

Portland VA Medical Center

Portland, Oregon, United States

Nashville VA Medical Center

Nashville, Tennessee, United States

Seattle VA Medical Center

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06441617


Related Trials